Bora Pharmaceuticals Co. Ltd., a pharmaceutical manufacturer, and Corealis Pharma Inc., an early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration aims to simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.

Biotech and pharmaceutical innovators will now have access to both Bora’s global commercial infrastructure and Corealis’ expertise in formulation development and clinical-scale manufacturing. The collaboration creates a simple, more efficient route to bring new medicines to patients faster and more reliably.

“This collaboration is all about bridging capability and culture,” said J.D. Mowery, President of Bora’s CDMO division. “By combining Bora’s scale-up strength with Corealis’ early-phase expertise and leveraging the customer service and reliability focus of both organizations, we’re setting a new standard for CDMO collaboration.”

Together, the companies will offer unified project management and aligned quality so that biotech and pharmaceutical companies can minimize outsourcing risk by working with an integrated CDMO alliance from discovery to commercial launch.

“Emerging biotechs often face timeline and flexibility challenges when scaling promising therapies from clinical to commercial lots,” said David Leroux-Petersen, CEO of Corealis Pharma. “The alliance with Bora provides our early-stage partners with a clear, fast, seamless, simple path to phase III manufacturing and commercial launch.”